WO2024017814A1 - Co-cristal d'urolithine a-bétaïne (i) - Google Patents
Co-cristal d'urolithine a-bétaïne (i) Download PDFInfo
- Publication number
- WO2024017814A1 WO2024017814A1 PCT/EP2023/069751 EP2023069751W WO2024017814A1 WO 2024017814 A1 WO2024017814 A1 WO 2024017814A1 EP 2023069751 W EP2023069751 W EP 2023069751W WO 2024017814 A1 WO2024017814 A1 WO 2024017814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal
- compound
- crystal according
- products
- formula
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 78
- 229930186301 urolithin Natural products 0.000 title description 2
- RIUPLDUFZCXCHM-UHFFFAOYSA-N Urolithin A Chemical compound OC1=CC=C2C3=CC=C(O)C=C3OC(=O)C2=C1 RIUPLDUFZCXCHM-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229960003237 betaine Drugs 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 6
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 150000004292 cyclic ethers Chemical class 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229960004132 diethyl ether Drugs 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 3
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 3
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 3
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 150000003462 sulfoxides Chemical class 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 229920001968 ellagitannin Polymers 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Definitions
- the present invention relates to a specific multicomponent crystalline system (cocrystal) comprising Urolithin A as one of the components produced by a specific process.
- Urolithin A is the compound of formula (I)
- Urolithin A is a metabolite compound resulting from the transformation of ellagitannins by the gut bacteria in the body.
- Urolithin A belongs to the class of organic compounds known as benzo-coumarins or dibenzo-a-pyrones. Its precursors - ellagic acids and ellagitannins - are ubiquitous in nature, including edible plants, such as pomegranates, strawberries, raspberries, and walnuts.
- Urolithin A was isolated and identified in the 1960s.
- Urolithin A is a natural food metabolite of the gut microbiome that has been shown to stimulate mitophagy and improve muscle function in aged animals and in models of muscular dystrophy, while also being safe, bioavailable, and able to induce mitochondrial gene expression in older adults.
- Urolithin A Due to the fact, that Urolithin A is not to be found in a natural source, the precursors are supplied and then transformed into Urolithin A in the gut system.
- Urolithin A is available commercially from a variety of suppliers.
- Urolithin A has poor water solubility (pg/mL) and low bioavailability. Therefore, a large loading (500 mg per serving) is usually used in the current formulation to achieve an acceptable result.
- the cocrystal according to the present invention is obtained by using the solvent process.
- the solvent process comprises the steps of: a) stirring a mixture of a compound of formula (I) and the compound of formula (II) and the co-crystal forming compound in at least one solvent, at a temperature between 10 and 40°C, b) cooling the mixture to room temperature if the temperature of the resulting mixture of the step a) is higher than room temperature, and c) isolating the obtained compound.
- the present invention relates to the co-crystal (CC) obtainable by a) stirring a mixture of a compound of formula (I) and the compound of formula (II) and the co-crystal forming compound in at least one solvent, at a temperature between 10 and 40°C, b) cooling the mixture to room temperature if the temperature of the resulting mixture of the step a) is higher than room temperature, and c) isolating the so obtained compound.
- the second component of a co-crystal is also referred to as co-former.
- this co-formed is the compound of formula (II), which is known as betaine (or N,N,N-trimethylglycine).
- co-crystal or “co-crystal” refers herein a crystal formed by combining two or more organic molecules in the same crystal lattice through non-covalent bonds (hydrogen bond, TT-TT stacking, van der Waals force, etc.) in a fixed stoichiometric ratio. It is a way of aggregating of multi-component substances in a solid state.
- a first neutral component crystallizes with at least one second neutral component and interacts via non-ionic interactions.
- Said at least one second component in the co-crystal is commonly referred to as a “coformer” or “co-crystal former” and is solid at room temperature and atmospheric pressure.
- This definition distinguishes co-crystals from crystalline solvates, in that in a solvate one of the components is a liquid at room temperature and atmospheric pressure.
- the co-crystal’s components are in a neutral state and are linked by hydrogen bonding and other non-ionic interactions.
- the co-crystal according to the present invention comprises Urolithin A and betaine.
- the molar ratio of Urolithin A : betaine in the co-crystral is 1 :1.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC1 ), which is the co-crystal (CC), wherein molar ratio of Urolithin A : betaine is 1 :1.
- the solvents which are used in the solvent process, are polar or non-polar solvents, which can be protic or non-protic.
- Suitable solvents are i.e. , alcohols, aromatic hydrocarbons, aliphatic hydrocarbons, non-cyclic ethers, cyclic ethers, esters, ketones, sulfoxides and nitriles.
- Suitable solvents are i.e. water, acetonitrile, benzonitrile, dichloromethane, chloroform, dimethylsulfoxide, methanol, ethanol, isopropyl alcohol, iso pentanol, ethyl acetate, isopentyl acetate, isobutyl acetate, n-butyl acetate, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, diethylether, methyl tert-butyl ether, toluene, cyclohexane, xylene and heptane, preferably water, ethyl acetate, acetonitrile, methanol and ethanol.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC2), which is the co-crystal (CC) or (CC1 ), wherein the at least one solvent is polar or non-polar solvents, which can be protic or non-protic.
- CC2 specific multicomponent crystalline system
- CC1 co-crystal
- the at least one solvent is polar or non-polar solvents, which can be protic or non-protic.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC2’), which is the co-crystal (CC) or (CC1 ), wherein the at least one solvent is chosen from the group consisting of water, alcohols, (aromatic) hydrocarbons, (cyclic) ethers, esters, ketones, sulfoxides and nitriles.
- CC2 specific multicomponent crystalline system
- the at least one solvent is chosen from the group consisting of water, alcohols, (aromatic) hydrocarbons, (cyclic) ethers, esters, ketones, sulfoxides and nitriles.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC2”), which is the co-crystal (CC) or (CC1 ), wherein the at least one solvent is chosen from the group consisting of water, acetonitrile, benzonitrile, dichloromethane, chloroform, dimethylsulfoxide, methanol, ethanol, isopropyl alcohol, iso pentanol, ethyl acetate, isopentyl acetate, isobutyl acetate, n-butyl acetate, acetone, methyl isobutyl ketone, tetrahydrofuran, 2-methyltetrahydrofuran, cyclopentyl methyl ether, diethylether, methyl tert-butyl ether, toluene, cyclohexane, xylene and heptane.
- the at least one solvent is chosen from the group consisting of water
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC2’”), which is the co-crystal (CC) or (CC1 ), wherein the at least one solvent is chosen from the group consisting of water, ethyl acetate, acetonitrile, methanol and ethanol.
- CC2 specific multicomponent crystalline system
- the at least one solvent is chosen from the group consisting of water, ethyl acetate, acetonitrile, methanol and ethanol.
- the amount of solvent used to obtain the co-crystal is at least 10pl per mg of the compound of formula (I) and of the compound of formula (II).
- the amount of the solvent is not critical.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC3), which is the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”) or (CC2’”), wherein the at least one solvent is used in an amount of at least 10p,l per mg of compound of formula (I) and of compound of formula (II).
- the compound of formula (I) is added in an equimolar amount in view of the compound of formula (II).
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC4), which is the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”) or (CC3), wherein the compound of formula (I) is added in an equimolar amount in view of the compound of formula (II).
- the process used to obtain the co-crystal is carried out at a temperature of 15 to 30°C, more preferably at room temperature.
- room temperature or its abbreviation “rt” is considered for a temperature between 20 to 25 °C.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC5), which is the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”), (CC3) or (CC4), wherein the process is carried out at a temperature of 15 to 30°C.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC5’), which is the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”), (CC3) or (CC4), wherein the process is carried out at room temperature.
- the present invention relates to a specific multicomponent crystalline system (co-crystal) (CC6), which is the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”), (CC3), (CC4), (CC5) or (CC5’), wherein the process is carried out at ambient pressure.
- the product obtained by the process according to the present invention can be isolated using commonly known methods (such as filtration, filtration under vacuum, evaporation, crystallization by cooling, heating-melting, decantation, and centrifugation, and other suitable techniques as known to a person skilled in the art).
- the obtained co-crystal of the invention may be purified, e.g. by recrystallization.
- the co-crystal can contain traces of the solvent used in the production of the cocrystal. This is depending on the drying (kind of drying as well as the length of drying).
- co-crystals of this invention are stable, wherein “stable” means that the cocrystals maintain their crystalline form over a long period of time at standard ambient conditions of temperature and pressure.
- the present invention also relates to the co-crystal of compound of formula (I) and of compound of formula (II), which is the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”), (CC3), (CC4), (CC5), (CC5’) or (CC6) characterised in that the X-ray diffraction pattern of the obtained co-crystal characteristic peaks exist at 20 angle: 5.98° ⁇ 0.2°, 11.64° ⁇ 0.2°, 14.98° ⁇ 0.2°, 18.26° ⁇ 0.2°, 21.02° ⁇ 0.2°, 22.18° ⁇ 0.2°, 22.68° ⁇ 0.2°, 23.18° ⁇ 0.2°, 26.04° ⁇ 0.2°, 30.80° ⁇ 0.2°.
- the present invention also relates to co-crystal of Urolithin A and betaine, characterized in that, the X-ray powder diffraction pattern of the co-crystal is shown substantially as the XRPD pattern of Fig. 3.
- the co-crystal according to the present invention has good handling properties of the solid form.
- the co-crystal has good flowability properties.
- the co-crystals according to the present invention may be used in compositions in the same way as other forms of Urolithin A previously known.
- the co-crystal according to the present invention can be used in food products, feed products, dietary supplements, pharmaceutical products as well as personal care products.
- the present invention relates to the use of the co-crystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”), (CC3), (CC4), (CC5), (CC5’) or (CC6) in food products, feed products, dietary supplements, pharmaceutical products and/or personal care products.
- the present invention relates to food products, feed products, dietary supplements, pharmaceutical products and/or personal care products comprising cocrystal (CC), (CC1 ), (CC2), (CC2’), (CC2”), (CC2’”), (CC3), (CC4), (CC5), (CC5’) or (CC6).
- any commonly known and used excipients can be added to the co-crystal.
- the amount of the co-crystal of the present invention (depends on the type of formulation and the desired dosage regimen during administration time periods.
- the amount in each oral formulation may be from 50 to 300 mg, preferably from 75 to 250 mg.
- Oral formulations may be solid formulations such as capsules, tablets, pills and troches, or a liquid suspension formulation.
- the crystalline composition according to the invention may be used directly as powders (micronized particles), granules, or suspensions, or they may be combined with other (pharmaceutically acceptable) ingredients in admixing the components and optionally finely divide them, and then filling capsules, composed for example from hard or soft gelatine: or compressing tablets, or troches, or suspend in suspensions. Coatings may also be applied.
- Acceptable ingredients are well known for the various types of formulation and may be for example binders such as natural or synthetic polymers, excipients, disintegrants, lubricants, surfactants, sweetening and other flavouring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, and carriers for the various formulation types.
- binders such as natural or synthetic polymers, excipients, disintegrants, lubricants, surfactants, sweetening and other flavouring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents, and carriers for the various formulation types.
- the so obtained co-crystal has a solubility in water, which is 3.4 higher than Urolithin A. (Fig.4)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un système cristallin multicomposant spécifique (co-cristal) comprenant de l'urolithine A en tant qu'un des composants produits selon un procédé spécifique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022106708 | 2022-07-20 | ||
CNPCT/CN2022/106708 | 2022-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024017814A1 true WO2024017814A1 (fr) | 2024-01-25 |
Family
ID=87473830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/069751 WO2024017814A1 (fr) | 2022-07-20 | 2023-07-17 | Co-cristal d'urolithine a-bétaïne (i) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024017814A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007127263A2 (fr) * | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Utilisations thérapeutiques d'urolithines |
-
2023
- 2023-07-17 WO PCT/EP2023/069751 patent/WO2024017814A1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007127263A2 (fr) * | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Utilisations thérapeutiques d'urolithines |
Non-Patent Citations (2)
Title |
---|
SHAHBAZ MUHAMMAD ET AL: "A new bioactive cocrystal of coumarin-3-carboxylic acid and thiourea: detailed structural features and biological activity studies", ACTA CRYSTALLOGRAPHICA SECTION C. CRYSTAL STRUCTURE COMMUNICATIONS, vol. 78, no. 3, 1 March 2022 (2022-03-01), DK, pages 192 - 200, XP093074842, ISSN: 0108-2701, DOI: 10.1107/S205322962200081X * |
ZHANG ZHIJIE ET AL: "Cocrystals of Natural Products: Improving the Dissolution Performance of Flavonoids Using Betaine", CRYSTAL GROWTH & DESIGN, vol. 19, no. 7, 3 July 2019 (2019-07-03), US, pages 3851 - 3859, XP093074682, ISSN: 1528-7483, DOI: 10.1021/acs.cgd.9b00294 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5463116A (en) | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them | |
KR20080064978A (ko) | 라퀴니모드 나트륨의 결정 및 이의 제조방법 | |
US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
WO2007013086A1 (fr) | Nouveaux polymorphes de tenofovir disoproxil fumarate | |
CA2912902A1 (fr) | Formes polymorphiques de chlorhydrate de nilotinib | |
IE51944B1 (en) | Zanthates and their therapeutic use | |
CN107522655B (zh) | 一种异烟肼、吡嗪酰胺与富马酸的三元共晶及其制备方法 | |
FR2898272A1 (fr) | Utilisation de derives du 3,5-seco-4-nor-cholestrane pour l'obtention d'un medicament cytoprotecteur | |
WO2024017814A1 (fr) | Co-cristal d'urolithine a-bétaïne (i) | |
WO2016189443A2 (fr) | Formes solides de phosphoramidate de nucléoside | |
JP2009527538A (ja) | Cd80アンタゴニストの塩 | |
WO2015052568A2 (fr) | Formes solides de curcumine et de dérivés de curcumine | |
WO2024017815A1 (fr) | Co-cristal d'urolithine a-bétaïne (ii) | |
AU2003206755B2 (en) | Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds | |
JP6534394B2 (ja) | S−アセチル グルタチオンの結晶形、その調製、および、医薬ならびに機能性食品製剤における使用 | |
KR101548724B1 (ko) | 고체 형태의 항바이러스제 및 이의 제조방법 | |
US20220135514A1 (en) | Cancer cell growth inhibiting composition and processed food | |
JPS63264549A (ja) | 乳酸カルシウム‐グリセロール付加物およびその製法 | |
JP2009520813A (ja) | カルバメート系抗生物質 | |
SK8295A3 (en) | N/exp_g/-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock | |
US3484524A (en) | Carboxylic acid - n - methyl-piperazides and their utilization as anthelmintics | |
JP2019524654A (ja) | 新しいタイプのタキサン化合物、その製造方法および適用 | |
CN117024378A (zh) | N’-[(3-烯丙基-2-羟基苯基)亚甲基]-2-(4-苄基-1-哌嗪基)乙酰肼酒石酸盐晶体及其制备方法和用途 | |
EP1785411A1 (fr) | Forme crystalline de proptriptyline hydrochloride | |
US20210332073A1 (en) | Process for the preparation of ferric citrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23745441 Country of ref document: EP Kind code of ref document: A1 |